Next report date
Report period
Q1 2024
EPS estimate
−0.51USD
Revenue estimate
232.00 KUSD
−9.1805USD
−26.48 MUSD
4.76 MUSD
9.17 M
About DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT)
Sector
CEO
Ebrahim Versi
Headquarters
San Diego
Website
Employees (FY)
11
Founded
2006
FIGI
BBG00XCCRGH4
DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0A4X is 0.0360 USD — it has increased by 2.86% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) stocks are traded under the ticker 0A4X.
DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
0A4X stock is 2.81% volatile and has beta coefficient of 0.73. Check out the list of the most volatile stocks — is DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) there?
DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) revenue for the last quarter amounts to 1.51 M USD despite the estimated figure of 500.00 K USD. In the next quarter revenue is expected to reach 1.60 M USD.
Yes, you can track DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
0A4X stock has fallen by 28.00% compared to the previous week, the month change is a 32.20% fall, over the last year DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) has showed a 99.44% decrease.
0A4X net income for the last quarter is −1.39 M USD, while the quarter before that showed −8.57 M USD of net income which accounts for 83.81% change. Track more DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) financial stats to get the full picture.
No, 0A4X doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0A4X shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 11.00 employees. See our rating of the largest employees — is DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) stock shows the sell signal. See more of DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) EBITDA is −18.25 M USD, and current EBITDA margin is −496.05%. See more stats in DMK PHARMACEUTICALS CORP COM USD0.0001 (POST REV SPLIT) financial statements.